Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5

Author: Benzinga Newsdesk | March 28, 2024 06:51am
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform rating and announces Price Target of $5.

Posted In: XERS